OTCPK:AXRX

Stock Analysis Report

Executive Summary

Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products.

Risk Analysis

Shares are highly illiquid

High level of non-cash earnings

Latest financial reports are more than a year old

Does not have a meaningful market cap ($10M)



Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Amexdrug's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AXRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.8%

AXRX

2.6%

US Healthcare

0.8%

US Market


1 Year Return

-66.4%

AXRX

15.1%

US Healthcare

25.1%

US Market

Return vs Industry: AXRX underperformed the US Healthcare industry which returned 14.1% over the past year.

Return vs Market: AXRX underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

AXRXIndustryMarket
7 Day-12.8%2.6%0.8%
30 Day-12.8%3.0%3.1%
90 Day-25.3%18.8%10.9%
1 Year-66.4%-66.4%17.1%15.1%27.7%25.1%
3 Year-36.8%-36.8%52.3%45.6%51.3%41.6%
5 Year-57.8%-57.8%67.1%55.6%77.2%57.6%

Price Volatility Vs. Market

How volatile is Amexdrug's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Amexdrug undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Amexdrug is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Amexdrug has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of AXRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Amexdrug regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Amexdrug forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amexdrug has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of AXRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Amexdrug's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Amexdrug performed over the past 5 years?

13.5%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Amexdrug has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

  • When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Amexdrug's' management and board experience and expertise to assess their ability to deliver on their strategic promises.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Amexdrug's filings and announcements here.
  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Amexdrug's financial position?


In this section we usually analyse Amexdrug's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Amexdrug has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of AXRX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Amexdrug's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Amexdrug's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Amexdrug's salary, the management and board of directors tenure and is there insider trading?

US$155k

CEO Compensation


CEO

Jack Amin (60yo)

19.8yrs

Tenure

US$154,800

Compensation

Mr. Jack Amin serves as the Chairman of Amexdrug Corp. and has been its Chief Executive Officer, President, Secretary and Treasurer since April 2000. Mr. Jack serves as the Chief Financial Officer, Chief  ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Jack Amin (60yo)

    Chairman

    • Tenure: 19.8yrs
    • Compensation: US$154.80k

Board Members

  • Jack Amin (60yo)

    Chairman

    • Tenure: 19.8yrs
    • Compensation: US$154.80k
  • Rodney Barron (66yo)

    Independent Director

    • Tenure: 18.1yrs
  • Ben Meimand (70yo)

    Independent Director

    • Tenure: 18.1yrs
  • Humberto Zardo

    Advisor to the Board of Directors

    • Raymond Chow

      Advisor to the Board of Directors

      • Ike Alabata

        Advisor to the Board of Directors

        Company Information

        Amexdrug Corporation's company bio, employee growth, exchange listings and data sources


        Key Information

        • Name: Amexdrug Corporation
        • Ticker: AXRX
        • Exchange: OTCPK
        • Founded: 1963
        • Industry: Health Care Distributors
        • Sector: Healthcare
        • Market Cap: US$9.826m
        • Shares outstanding: 169.41m
        • Website: https://www.amexdrug.com

        Location

        • Amexdrug Corporation
        • 7251 Condor Street
        • Commerce
        • California
        • 90040
        • United States

        Listings

        TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
        AXRXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 1972

        Biography

        Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of prescription and over-the-counter drugs, non-drug products, and health and beauty products; and private manufacturing and labeling activities. Further, the company manufactures and sells facial and body creams, arthritic pain relief medications, and hair and nail care products to pharmacies, beauty salons, beauty supply stores, and other fine shops. Amexdrug Corporation markets its products under the Sponix name. The company distributes its products through its subsidiaries primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities, and other wholesalers and retailers in the state of California. The company was formerly known as Harlyn Products, Inc. and changed its name to Amexdrug Corporation in April 2000 to reflect the change in its business to the sale of pharmaceutical products. Amexdrug Corporation was founded in 1963 and is based in Commerce, California. 


        Company Analysis and Financial Data Status

        All financial data provided by Standard & Poor's Capital IQ.
        DataLast Updated (UTC time)
        Company Analysis2020/01/21 23:31
        End of Day Share Price2020/01/21 00:00
        Earnings2013/06/30
        Annual Earnings2012/12/31


        Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.